Patients with HER-2 positive early breast cancer with residual invasive disease after neoadjuvant therapy were randomly ...

Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine ...

Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug ...

The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) has reached its enrollment goal of 108,508 women, as announced ...

Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...

Cancer diagnoses are shifting from older to younger adults and from men to women, according to a report released Thursday by ...

The overall average breast cancer incidence rate in the U.S. was 131.8 per 100,000 and the overall average breast cancer mortality rate was 19.3 per 100,000. Among women in the U.S., breast cancer ...

A combination therapy of two drugs — a statin and a protein inhibitor — may help suppress the creation and growth of tumors ...

A Cancer Journal for Clinicians. It appears that breast and thyroid cancers in women are driving this increasing trend. “Breast and thyroid cancer account for almost half of all cancer diagnoses ...

CDK4/6 inhibitors like abemaciclib and ribociclib improve invasive disease-free survival in breast cancer trials, but controversy surrounds study designs, bias, and cost-effectiveness, raising ...

Data has revealed that British women under 50 are approximately 70% more likely to develop cancer than men of the same age, ...